Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease [Globe and Mail, The (Toronto, Canada)]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Globe and Mail, The
TORONTO Nov. 28, 2024 /CNW/ - Takeda Canada Inc. (Takeda) congratulates the recipients of the Canadian Inflammatory Bowel Disease Research Consortium (CIRC) $1 million PIONEER Grant to support innovative, high-quality Canadian clinical research to improving patient outcomes and quality of life for those living with inflammatory bowel disease (IBD). Takeda is a co-sponsor of the grant, contributing of the award. This year's recipients are Dr. Kevan Jacobson , Investigator, BC Children's Hospital and Head, Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Faculty of Medicine, University of British Columbia and Dr. Genelle Lunken , Investigator, BC Children's Hospital, Registered Dietitian, IBD Centre of BC, for their study Open Label Multicentre Randomized Dietary Intervention Study in Pediatric Crohn Disease Patients Initiating Anti-TNF Therapy (DISPENSE-T) Supported by Crohn's and Colitis Canada, CIRC was established in 2017 to promote and facilita
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic AreasBusiness Wire
- Dietary Supplements Market in Japan is Expected to Reach USD 2,310.30 Million by 2033, Growing at a 6.2% CAGR | Future Market Insights, Inc. [Yahoo! Finance]Yahoo! Finance
- Takeda Pharmaceutical (TSE:4502) Advances with New Product Update and Strategic Alliances for Growth [Yahoo! Finance]Yahoo! Finance
- Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros TherapeuticsBusiness Wire
TAK
Sec Filings
- 12/18/24 - Form 6-K
- 12/13/24 - Form 6-K
- 12/2/24 - Form 6-K
- TAK's page on the SEC website